152 related articles for article (PubMed ID: 24131915)
1. Endothelin receptor antagonists and scleroderma related digital ulcers.
Lee WY; Faruqi S; Morice AH
Acta Reumatol Port; 2013; 38(1):58-9. PubMed ID: 24131915
[No Abstract] [Full Text] [Related]
2. Connective tissue diseases: Treatment of digital ulcers in systemic sclerosis.
Lambova S; Müller-Ladner U
Nat Rev Rheumatol; 2011 Jan; 7(1):5-6. PubMed ID: 21119606
[No Abstract] [Full Text] [Related]
3. Management of digital vasculopathy in systemic sclerosis: benefits of multiple courses of endothelin-1 receptor antagonists.
Ngcozana T; Ong V; Denton CP
BMJ Case Rep; 2014 Mar; 2014():. PubMed ID: 24682137
[TBL] [Abstract][Full Text] [Related]
4. Bosentan as a rescue therapy in scleroderma refractory digital ulcers.
Chamaillard M; Heliot-Hosten I; Constans J; Taïeb A
Arch Dermatol; 2007 Jan; 143(1):125-6. PubMed ID: 17224564
[No Abstract] [Full Text] [Related]
5. Effect of the endothelin type A-selective endothelin receptor antagonist ambrisentan on digital ulcers in patients with systemic sclerosis: results of a prospective pilot study.
Chung L; Ball K; Yaqub A; Lingala B; Fiorentino D
J Am Acad Dermatol; 2014 Aug; 71(2):400-1. PubMed ID: 25037794
[No Abstract] [Full Text] [Related]
6. Safety and tolerability of bosentan for digital ulcers in Japanese patients with systemic sclerosis: Prospective, multicenter, open-label study.
Hamaguchi Y; Sumida T; Kawaguchi Y; Ihn H; Tanaka S; Asano Y; Motegi SI; Kuwana M; Endo H; Takehara K
J Dermatol; 2017 Jan; 44(1):13-17. PubMed ID: 27374274
[TBL] [Abstract][Full Text] [Related]
7. Successful treatment of systemic sclerosis-related digital ulcers and sarcoidosis with endothelin receptor antagonist (bosentan) therapy.
Tillon J; Hervé F; Chevallier D; Muir JF; Levesque H; Marie I
Br J Dermatol; 2006 May; 154(5):1000-2. PubMed ID: 16634913
[No Abstract] [Full Text] [Related]
8. Prostaglandin E1 therapy for digital ulcers in scleroderma.
Baron M; Skrinskas G; Urowitz MB; Madras PN
Can Med Assoc J; 1982 Jan; 126(1):42-5. PubMed ID: 7199370
[No Abstract] [Full Text] [Related]
9. [Digital ulcers in systemic sclerosis: use of endotheline antagonists].
Mota J; Castellano A; Santiago F; Carvalho P; Madeira AS; Pereira De Moura JM; Nascimento Costa JM
Acta Med Port; 2011; 24(5):837-42. PubMed ID: 22525638
[TBL] [Abstract][Full Text] [Related]
10. [Digital ulcers in systemic sclerosis].
Guillevin L
Presse Med; 2008 Apr; 37(4 Pt 2):735-6. PubMed ID: 18258409
[No Abstract] [Full Text] [Related]
11. Successful treatment of systemic sclerosis digital ulcers and pulmonary arterial hypertension with endothelin receptor antagonist bosentan.
Humbert M; Cabane J
Rheumatology (Oxford); 2003 Jan; 42(1):191-3. PubMed ID: 12509640
[No Abstract] [Full Text] [Related]
12. Successful treatment of systemic-sclerosis-related digital ulcers with a selective endothelin type A receptor antagonist (sitaxentan).
Gholam P; Sehr T; Enk A; Hartmann M
Dermatology; 2009; 219(2):171-3. PubMed ID: 19590168
[TBL] [Abstract][Full Text] [Related]
13. Digital Ulcers, Systemic Sclerosis Sine Scleroderma and Paraneoplastic Phenomena Responding to Bosentan Therapy.
Sharabi I; Tanay A; Zandman-Goddard G
Isr Med Assoc J; 2015 Feb; 17(2):126-7. PubMed ID: 26223094
[No Abstract] [Full Text] [Related]
14. Resolution of severe digital ulceration during a course of Bosentan therapy.
Snyder MJ; Jacobs MR; Grau RG; Wilkes DS; Knox KS
Ann Intern Med; 2005 May; 142(9):802-3. PubMed ID: 15867420
[No Abstract] [Full Text] [Related]
15. Effect of a sequential therapy of bosentan and iloprost versus a monotherapy with bosentan in the treatment of scleroderma related digital ulcers.
Hafner F; Thomas G; Froehlich H; Steidl K; Brodmann M
Int Angiol; 2011 Oct; 30(5):493-5. PubMed ID: 21804491
[No Abstract] [Full Text] [Related]
16. Ironic case of hepatic dysfunction following the global withdrawal of sitaxentan.
Don GW; Joseph F; Celermajer DS; Corte TJ
Intern Med J; 2012 Dec; 42(12):1351-4. PubMed ID: 23253000
[TBL] [Abstract][Full Text] [Related]
17. Bosentan for digital ulcers in patients with systemic sclerosis: a prospective 3-year followup study.
Tsifetaki N; Botzoris V; Alamanos Y; Argyriou E; Zioga A; Drosos AA
J Rheumatol; 2009 Jul; 36(7):1550-2. PubMed ID: 19567637
[No Abstract] [Full Text] [Related]
18. [Digital ulcers in systemic scleroderma].
Lok C; Mouthon L; Ségard M; Richard MA; Guillevin L
Ann Dermatol Venereol; 2011 Nov; 138(11):762-8; quiz 761, 769. PubMed ID: 22078040
[No Abstract] [Full Text] [Related]
19. Effect of Macitentan on the Development of New Ischemic Digital Ulcers in Patients With Systemic Sclerosis: DUAL-1 and DUAL-2 Randomized Clinical Trials.
Khanna D; Denton CP; Merkel PA; Krieg T; Le Brun FO; Marr A; Papadakis K; Pope J; Matucci-Cerinic M; Furst DE; ;
JAMA; 2016 May; 315(18):1975-88. PubMed ID: 27163986
[TBL] [Abstract][Full Text] [Related]
20. Oral sildenafil for the treatment of Raynaud's phenomenon and digital ulcers secondary to systemic sclerosis.
Gore J; Silver R
Ann Rheum Dis; 2005 Sep; 64(9):1387. PubMed ID: 16100356
[No Abstract] [Full Text] [Related]
[Next] [New Search]